The in vivo results collectively indicate that efficient anti-tumor activity resulting from the combination of fatostatin and docetaxel treatment is associated with deregulation of the SREBP-mediated pathways in PCa, especially those with p53 mutations. The gene discussed is TP53; the disease is neoplasm.